Recombinant Human Interleukin-17A/F Heterodimer (C-6His)

Cat.No.: CI60

Recombinant Human IL-17A&17F (C-6His)
Description
Recombinant Human Interleukin-17A/Interleukin-17F Heterodimer is produced by our Mammalian expression system and the target gene encoding Gly24-Ala155&Arg31-Gln163 is expressed with a 6His tag at the C-terminus.
Accession #:Q16552&Q96PD4
Known as:IL?17A/F Heterodimer;IL-17A&IL-17F Heterodimer
Formulation
Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.4.
Quality Control
Purity:Greater than 90% as determined by reducing SDS-PAGE.
BioActivity:Measured by its ability to induce IL-6 secretion by NIH-3T3 mouse embryonic fibroblast cells.
Endotoxin:Less than 0.1 ng/?g (1 EU/?g) as
Reconstitution
Always centrifuge tubes before opening. Do not mix by vortex or pipetting.
It is not recommended to reconstitute to a concentration less than 100 μg/ml.
Dissolve the lyophilized protein in ddH2O.
Please aliquot the reconstituted solution to
Storage
Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.
Reconstituted protein solution can be stored at 4-7°C for 2-7 days.
Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Background
The IL-17 family include IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (also called IL-25), and IL-17F. The family is comprised of at least six proinflammatory cytokines that share a conserved cysteine-knot structure but diverge at the N-terminus. All members of the IL-17 family have a similar protein structure, with four highly conserved cysteine residues critical to their 3-dimensional shape, yet they have no sequence similarity to any other known cytokines. IL-17 family members are glycoproteins secreted as dimers that induce local cytokine production and recruit granulocytes to sites of inflammation. IL-17 is induced by IL-15 and IL-23, mainly in activated CD4+ T cells distinct from Th1 or Th2 cells. IL-17F is the most homologous to IL-17, but is induced only by IL-23 in activated monocytes.
Publication
Preclinical development of GR1501, a human monoclonal antibody that neutralizes interleukin-17A Yunlong Shan , et al. (Biochemical and Biophysical Research Communications, 2019)+

Send Message